Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

European stocks slip ahead of US inflation data, GSK jumps



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-European stocks slip ahead of US inflation data, GSK jumps</title></head><body>

Tech stocks lead morning slide

U.S. inflation data at 1230 GMT

GSK to settle Zantac lawsuits, stock up

Updated at 0825 GMT

By Paolo Laudani and Sruthi Shankar

Oct 10 (Reuters) - European shares slipped on Thursday, with technology and mining stocks leading losses, while investors looked out U.S. inflation data for hints on the Federal Reserve's next policy easing moves.

The pan-European STOXX 600 index .STOXX was down 0.2%, with tech .SX8P, mining .SXPP and travel and leisure .SXTP stocks leading morning declines.

European stocks were under pressureas bondyields rose on Thursday, with the German 10-year yield hitting a fresh one-month high, tracking overnight gains in U.S. Treasury yields. US/

Wall Street indexes touched record highs on Wednesday after the Fed's September meeting minutes showed a "substantial majority" of officials supported an outsized half-point rate cut, without committing to a particular pace of cuts in the future.

Data at 1230 GMT (8:30 a.m. ET) is expected to show U.S. consumer prices rose 0.1% in September on a month-over-month basis, compared with a 0.2% increase in August. Traders are currently pricing in an 85% chance of a smaller 25-basis-point reductionfrom the Fed next month.

"Markets are muted as they're waiting to see what happens with the U.S.CPI (consumer price index) and, more importantly, what's happening on Saturday morning in China," said Stefan Koopman, senior market economist at Rabobank.

"If we get a cooler-than-expected CPI, it won't raise expectations of a 50-basis-point cut; I think the risk is not symmetrical on that report."

The STOXX 600 has been choppy this week as uncertainty around Beijing'sstimulus plans weighed on sentiment. China's finance ministry will detail plans on fiscal stimulus at a highly anticipated news conference on Saturday.

Investors will also focus on the French government's 2025 budget later on Thursday, with plans for 60 billion euros ($65.68 billion) worth of tax hikes and spending cuts to tackle a spiralling fiscal deficit.

Markets are likely to pay close attention to whether the budget can get through parliament without being watered down too much.

"It should be a very credible budget and if it's not, French assets will be at risk tomorrow morning," said Rabobank's Koopman.

Among individual stocks, GSK GSK.L jumped 5.2% after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer. The figure was smaller than what some analysts had feared.

Shares in Italy's fourth-largest bank BPER EMII.MI rose 7.6% to touch a nine-year high after the lender provided a new 2024-2027 business plan.



Reporting by Paolo Laudani in Gdansk and Sruthi Shankar in Bengaluru; Editing by Eileen Soreng and Sonia Cheema

</body></html>

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.